Literature DB >> 34011976

Involvement of the dopaminergic system in the reward-related behavior of pregabalin.

Yusuf S Althobaiti1,2,3, Farooq M Almutairi4,5,6, Fahad S Alshehri7, Ebtehal Altowairqi8, Aliyah M Marghalani4, Amal A Alghorabi4, Walaa F Alsanie4,9, Ahmed Gaber4,10, Hashem O Alsaab4,11, Atiah H Almalki4,12, Alqassem Y Hakami13,14, Turki Alkhalifa15, Ahmad D Almalki15, Ana M G Hardy16, Zahoor A Shah17.   

Abstract

There has been an increase in cases of drug addiction and prescription drug abuse worldwide. Recently, pregabalin abuse has been a focus for many healthcare agencies, as highlighted by epidemiological studies. We previously evaluated the possibility of pregabalin abuse using the conditioned place preference (CPP) paradigm. We observed that a 60 mg/kg dose could induce CPP in mice and that pregabalin-rewarding properties were mediated through glutamate neurotransmission. Notably, the dopaminergic reward circuitry is also known to play a crucial role in medication-seeking behavior. Therefore, this study aimed to explore the possible involvement of dopaminergic receptor-1 in pregabalin-induced CPP. Mice were randomly allocated to receive saline or the dopamine-1 receptor antagonist SKF-83566 (0.03 mg/kg, intraperitoneal). After 30 min, the mice received either saline or pregabalin (60 mg/kg) during the conditioning phase. Among the control groups that received saline or SKF-83566, the time spent in the two conditioning chambers was not significantly altered. However, among the pregabalin-treated group, there was a marked increase in the time spent in the drug-paired chamber compared to the time spent in the vehicle-paired chamber. Notably, blocking dopamine-1 receptors with SKF-83566 completely prevented pregabalin-induced place preference, thus demonstrating the engagement of the dopaminergic system in pregabalin-induced reward-related behavior.

Entities:  

Year:  2021        PMID: 34011976     DOI: 10.1038/s41598-021-88429-8

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  104 in total

1.  Anticonvulsants as anxiolytics, part 2: Pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels.

Authors:  Stephen M Stahl
Journal:  J Clin Psychiatry       Date:  2004-04       Impact factor: 4.384

Review 2.  Prescription drug abuse: an epidemic dilemma.

Authors:  Robert L DuPont
Journal:  J Psychoactive Drugs       Date:  2010-06

3.  Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data.

Authors:  Fabrizio Schifano; Stefano D'Offizi; Michele Piccione; Ornella Corazza; Paolo Deluca; Zoe Davey; Giuditta Di Melchiorre; Lucia Di Furia; Magí Farré; Liv Flesland; Miia Mannonen; Aino Majava; Stefania Pagani; Teuvo Peltoniemi; Holger Siemann; Arvid Skutle; Marta Torrens; Cinzia Pezzolesi; Peer van der Kreeft; Norbert Scherbaum
Journal:  Psychother Psychosom       Date:  2011-01-04       Impact factor: 17.659

4.  A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder.

Authors:  Mark J Boschen
Journal:  Can J Psychiatry       Date:  2011-09       Impact factor: 4.356

Review 5.  Pregabalin: its pharmacology and use in pain management.

Authors:  Noor M Gajraj
Journal:  Anesth Analg       Date:  2007-12       Impact factor: 5.108

Review 6.  The potential of pregabalin in neurology, psychiatry and addiction: a qualitative overview.

Authors:  Giovanni Martinotti; Matteo Lupi; Fabiola Sarchione; Rita Santacroce; Anatolia Salone; Domenico De Berardis; Nicola Serroni; Marilde Cavuto; Maria Signorelli; Eugenio Aguglia; Alessandro Valchera; Felice Iasevoli; Massimo Di Giannantonio
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

7.  Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study.

Authors:  Douglas E Feltner; Maria Liu-Dumaw; Edward Schweizer; Robert Bielski
Journal:  Int Clin Psychopharmacol       Date:  2011-07       Impact factor: 1.659

8.  Potential misuse of pregabalin and gabapentin.

Authors:  Hannah Loftus; Alison Wright
Journal:  BMJ       Date:  2014-02-05

Review 9.  A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.

Authors:  Howard N Bockbrader; David Wesche; Raymond Miller; Sunny Chapel; Nancy Janiczek; Paula Burger
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

Review 10.  Safety issues around misuse of antiepileptics.

Authors:  Barbara Piskorska; Barbara Miziak; Stanisław J Czuczwar; Kinga K Borowicz
Journal:  Expert Opin Drug Saf       Date:  2013-05-04       Impact factor: 4.250

View more
  2 in total

1.  The Effects of Prenatal Exposure to Pregabalin on the Development of Ventral Midbrain Dopaminergic Neurons.

Authors:  Walaa F Alsanie; Majid Alhomrani; Ahmed Gaber; Hamza Habeeballah; Heba A Alkhatabi; Raed I Felimban; Sherin Abdelrahman; Charlotte A E Hauser; Adeel G Chaudhary; Abdulhakeem S Alamri; Bassem M Raafat; Abdulwahab Alamri; Sirajudheen Anwar; Khaled A Alswat; Yusuf S Althobaiti; Yousif A Asiri
Journal:  Cells       Date:  2022-03-01       Impact factor: 6.600

2.  Prenatal Exposure to Gabapentin Alters the Development of Ventral Midbrain Dopaminergic Neurons.

Authors:  Walaa F Alsanie; Sherin Abdelrahman; Majid Alhomrani; Ahmed Gaber; Hamza Habeeballah; Heba A Alkhatabi; Raed I Felimban; Charlotte A E Hauser; Hossam H Tayeb; Abdulhakeem S Alamri; Bassem M Raafat; Sirajudheen Anwar; Khaled A Alswat; Yusuf S Althobaiti; Yousif A Asiri
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.